123 results on '"Wong, Kwok"'
Search Results
2. Repurposing cetylpyridinium chloride and domiphen bromide as phosphoethanolamine transferase inhibitor to combat colistin-resistant Enterobacterales
3. Discovery of a novel class of rosmarinic acid derivatives as antibacterial agents: Synthesis, structure-activity relationship and mechanism of action
4. Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
5. Cholangiocarcinoma across England: Temporal changes in incidence, survival and routes to diagnosis by region and level of socioeconomic deprivation
6. Cancer-Associated Fibroblasts in Esophageal Cancer
7. Impulse control and related behavioral disorders (ICRD) in Idiopathic Parkinson’s Disease treated with different dopamine agonists in Hong Kong: Is any dopamine agonist better?
8. FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression
9. SAT-515 Cholangiocarcinoma across England: evidence of regional, socioeconomic, and temporal variations in incidence, survival, routes to diagnosis and treatment
10. Utilization of circulating tumor DNA (ctDNA) testing by race and ethnicity in more than 135,000 patients.
11. Array-based specific classification of bacterial species via hydrophilic/hydrophobic biosensors.
12. Supplementary Figure S9 from Acquired Cross-Resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC Paralogs
13. Supplementary Tables from Acquired Cross-Resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC Paralogs
14. Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer
15. Acquired Cross-Resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC Paralogs
16. Supplementary Table 5 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
17. FIGURE 2 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
18. Supplementary Figure 4 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
19. FIGURE 4 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
20. FIGURE 6 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
21. Supplementary Figure 6 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
22. Supplementary Table 1 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
23. Fluorescently Modified NDM-1: A Versatile Drug Sensor for Rapid In Vitro β-Lactam Antibiotic and Inhibitor Screening
24. Supplementary Figure 2 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
25. FIGURE 5 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
26. Supplementary Table 4 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
27. Supplementary Table 2 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
28. Supplementary Figure 3 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
29. Supplementary Table 3 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
30. Supplementary Table 6 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
31. FIGURE 1 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
32. Supplementary Figure 1 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
33. FIGURE 3 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
34. Supplementary Figure 5 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
35. Data from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
36. A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
37. EZH2 inhibition promotes tumor immunogenicity in lung squamous cell carcinomas
38. Impulse control and related behavioral disorders (ICRD) in Idiopathic Parkinson’s Disease treated with different dopamine agonists in Hong Kong: Is any dopamine agonist better?
39. Quasi-Projective Manifolds Uniformized by Carathéodory Hyperbolic Manifolds and Hyperbolicity of Their Subvarieties.
40. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
41. Treatment-related Complications in Children with Cancer
42. EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation
43. Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway
44. Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection.
45. Characterization of tumor heterogeneity through segmentation-free representation learning.
46. Deconvolution of the tumor-educated platelet transcriptome reveals activated platelet and inflammatory cell transcript signatures.
47. CORR Insights®: Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
48. Apathy in subarachnoid hemorrhage: study protocol for a 1-year follow-up study.
49. Controversies in orthopaedic oncology.
50. Spatial engineering of single-atom Fe adjacent to Cu-assisted nanozymes for biomimetic O 2 activation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.